Arbutus Sues Pfizer and BioNTech Over Lipid Nanoparticle Patents
The biotech firm and licensee Genevant filed international lawsuits while collecting first payment from Moderna settlement and signaling shareholder returns.
Arbutus Biopharma and its exclusive licensee Genevant have initiated three international lawsuits against Pfizer and BioNTech seeking to enforce patents that protect their lipid nanoparticle technology, a core component in mRNA vaccine development.
The enforcement actions represent an escalation in Arbutus's strategy to monetize its LNP intellectual property portfolio, which has become central to the commercial success of mRNA-based therapeutics. The company did not disclose the specific jurisdictions or the damages sought in the litigation.
The litigation coincides with Arbutus receiving its first payment under a settlement agreement reached with Moderna, according to the company announcement. Arbutus did not specify the payment amount or the terms of the broader settlement arrangement with Moderna.
Following these developments, Arbutus announced its intent to return capital to shareholders, though the company provided no details regarding the timing, structure, or magnitude of the proposed distribution. The capital return signals confidence in the company's near-term cash generation from its existing licensing agreements and litigation settlements.
Lipid nanoparticles have emerged as a critical enabling technology for mRNA vaccines and therapeutics, with Pfizer and BioNTech's Comirnaty vaccine and Moderna's Spikevax generating billions in annual revenue. Patent disputes over LNP formulations and delivery mechanisms have become increasingly common as multiple companies hold overlapping intellectual property claims in the space. Arbutus's decision to pursue enforcement against two of the largest manufacturers suggests the company views its patent position as defensible across multiple international markets.
The outcome of these cases could establish precedent for LNP patent validity and scope, with implications for other licensees and developers of mRNA therapeutics currently in development.